A Novel Function of Sphingosylphosphorylcholine on the Inhibitory Effects of Acetylcholinesterase Activity

Acetylcholine (ACh), a quaternary ammonium cation, is known as one of the itch inducer in atopic dermatitis (AD), an inflammatory skin disease with intense itching. Previous research has reported accumulation of ACh in lesional site of AD patients. Generally, ACh is metabolized by cholinesterase (Ch...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biological & pharmaceutical bulletin 2021/11/01, Vol.44(11), pp.1717-1723
Hauptverfasser: Kitazawa, Kazuyuki, Nagasawa-Shimura, Nanako, Tanaka, Kazunori, Musashi, Mina, Kubota, Yoshiki, Nagasawa, Teruaki, Yamaguchi, Yoko
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1723
container_issue 11
container_start_page 1717
container_title Biological & pharmaceutical bulletin
container_volume 44
creator Kitazawa, Kazuyuki
Nagasawa-Shimura, Nanako
Tanaka, Kazunori
Musashi, Mina
Kubota, Yoshiki
Nagasawa, Teruaki
Yamaguchi, Yoko
description Acetylcholine (ACh), a quaternary ammonium cation, is known as one of the itch inducer in atopic dermatitis (AD), an inflammatory skin disease with intense itching. Previous research has reported accumulation of ACh in lesional site of AD patients. Generally, ACh is metabolized by cholinesterase (ChE). Therefore, one of the causes of ACh accumulation may be the suppression of ChE activity. Increased levels of the multifunctional bioactive sphingolipid sphingosylphosphorylcholine (SPC) have also been detected in AD. Since SPC possesses a quaternary ammonium cation, like ACh, it is possible that SPC affects the activity of ChE catalyzing ACh metabolization. We investigated whether SPC influences the activity of ChE by performing enzymatic analysis of ChE in the presence of SPC. We found that SPC strongly suppressed acetylcholinesterase (AChE) activity, but the suppression of butyrylcholinesterase by SPC was quite low. The Michaelis constant (Km) of AChE in the presence of SPC increased, and the maximum velocity (Vmax) decreased, indicating that SPC acts as mixed-type inhibitor for AChE. The analysis of SPC analogs clarified the importance of both the quaternary ammonium cation and the carbon chain length of SPC for the AChE inhibitory effect and showed that SPC was unique in AChE inhibition among the sphingolipids in this study. These findings indicate a novel function of SPC on AChE inhibition. Thus, the inhibition activity of SPC may be a factor in the increase of ACh in AD.
doi_str_mv 10.1248/bpb.b21-00416
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2591210779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2591210779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c659t-9aa41687ca5056b2a3dba053c47cdd4936378138e511a56a9a5a157d4d34b51c3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhq0KRJe2x15RJC5cUjz-iJPjqrSlUgUH4Gw5jtN45Y2D7VTaf493U4LEwTOS55l3vhC6BnwDhNWf26m9aQmUGDOoztAGKBMlJ8DfoA1uoC4r4PU5eh_jDmMsMKHv0HlmoKlYvUG7bfHNvxhX3M-jTtaPhe-LH9Ngx2cfD24afMwvHJwevLOjKTKRBlM8joNtbcqR4q7vjU7xmLjVJq1oTCaoaPJnsi82HS7R2165aK5e_QX6dX_38_Zr-fT94fF2-1TqijepbJTKk9RCK4551RJFu1ZhTjUTuutYQysqaqC14QCKV6pRXAEXHesoazloeoE-LbpT8L_n3Ibc26iNc2o0fo6S8AYIYCGajH78D935OYy5uxPFgOKaZ6pcKB18jMH0cgp2r8JBApbHI8h8BJmPIE9HyPyHV9W53Ztupf9uPQMPC5CjVivnx-O-_tXWUbTWOy8JXkQZZAdCgjgZQmmTK5HjAF8WpV1M6tmspVRIVjtzaowxmdOzXTtcw3pQQZqR_gGe8rGj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2591413085</pqid></control><display><type>article</type><title>A Novel Function of Sphingosylphosphorylcholine on the Inhibitory Effects of Acetylcholinesterase Activity</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Kitazawa, Kazuyuki ; Nagasawa-Shimura, Nanako ; Tanaka, Kazunori ; Musashi, Mina ; Kubota, Yoshiki ; Nagasawa, Teruaki ; Yamaguchi, Yoko</creator><creatorcontrib>Kitazawa, Kazuyuki ; Nagasawa-Shimura, Nanako ; Tanaka, Kazunori ; Musashi, Mina ; Kubota, Yoshiki ; Nagasawa, Teruaki ; Yamaguchi, Yoko ; Inc ; aNANOEGG(R Research Laboratories ; bInstitute of Medical Science ; St.Marianna University School of Medicine</creatorcontrib><description>Acetylcholine (ACh), a quaternary ammonium cation, is known as one of the itch inducer in atopic dermatitis (AD), an inflammatory skin disease with intense itching. Previous research has reported accumulation of ACh in lesional site of AD patients. Generally, ACh is metabolized by cholinesterase (ChE). Therefore, one of the causes of ACh accumulation may be the suppression of ChE activity. Increased levels of the multifunctional bioactive sphingolipid sphingosylphosphorylcholine (SPC) have also been detected in AD. Since SPC possesses a quaternary ammonium cation, like ACh, it is possible that SPC affects the activity of ChE catalyzing ACh metabolization. We investigated whether SPC influences the activity of ChE by performing enzymatic analysis of ChE in the presence of SPC. We found that SPC strongly suppressed acetylcholinesterase (AChE) activity, but the suppression of butyrylcholinesterase by SPC was quite low. The Michaelis constant (Km) of AChE in the presence of SPC increased, and the maximum velocity (Vmax) decreased, indicating that SPC acts as mixed-type inhibitor for AChE. The analysis of SPC analogs clarified the importance of both the quaternary ammonium cation and the carbon chain length of SPC for the AChE inhibitory effect and showed that SPC was unique in AChE inhibition among the sphingolipids in this study. These findings indicate a novel function of SPC on AChE inhibition. Thus, the inhibition activity of SPC may be a factor in the increase of ACh in AD.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b21-00416</identifier><identifier>PMID: 34719648</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>acetylcholine ; Acetylcholinesterase ; Acetylcholinesterase - metabolism ; acetylcholinesterase inhibitor ; Ammonium ; Atopic dermatitis ; Cholinesterase Inhibitors - pharmacology ; Dose-Response Relationship, Drug ; Eczema ; Humans ; Neostigmine - pharmacology ; Phosphorylcholine - analogs &amp; derivatives ; Phosphorylcholine - pharmacology ; Pruritus ; quaternary ammonium cation ; Rivastigmine - pharmacology ; Skin diseases ; sphingolipid ; Sphingolipids ; Sphingosine - analogs &amp; derivatives ; Sphingosine - pharmacology ; Sphingosylphosphorylcholine</subject><ispartof>Biological and Pharmaceutical Bulletin, 2021/11/01, Vol.44(11), pp.1717-1723</ispartof><rights>2021 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c659t-9aa41687ca5056b2a3dba053c47cdd4936378138e511a56a9a5a157d4d34b51c3</citedby><cites>FETCH-LOGICAL-c659t-9aa41687ca5056b2a3dba053c47cdd4936378138e511a56a9a5a157d4d34b51c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34719648$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kitazawa, Kazuyuki</creatorcontrib><creatorcontrib>Nagasawa-Shimura, Nanako</creatorcontrib><creatorcontrib>Tanaka, Kazunori</creatorcontrib><creatorcontrib>Musashi, Mina</creatorcontrib><creatorcontrib>Kubota, Yoshiki</creatorcontrib><creatorcontrib>Nagasawa, Teruaki</creatorcontrib><creatorcontrib>Yamaguchi, Yoko</creatorcontrib><creatorcontrib>Inc</creatorcontrib><creatorcontrib>aNANOEGG(R Research Laboratories</creatorcontrib><creatorcontrib>bInstitute of Medical Science</creatorcontrib><creatorcontrib>St.Marianna University School of Medicine</creatorcontrib><title>A Novel Function of Sphingosylphosphorylcholine on the Inhibitory Effects of Acetylcholinesterase Activity</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>Acetylcholine (ACh), a quaternary ammonium cation, is known as one of the itch inducer in atopic dermatitis (AD), an inflammatory skin disease with intense itching. Previous research has reported accumulation of ACh in lesional site of AD patients. Generally, ACh is metabolized by cholinesterase (ChE). Therefore, one of the causes of ACh accumulation may be the suppression of ChE activity. Increased levels of the multifunctional bioactive sphingolipid sphingosylphosphorylcholine (SPC) have also been detected in AD. Since SPC possesses a quaternary ammonium cation, like ACh, it is possible that SPC affects the activity of ChE catalyzing ACh metabolization. We investigated whether SPC influences the activity of ChE by performing enzymatic analysis of ChE in the presence of SPC. We found that SPC strongly suppressed acetylcholinesterase (AChE) activity, but the suppression of butyrylcholinesterase by SPC was quite low. The Michaelis constant (Km) of AChE in the presence of SPC increased, and the maximum velocity (Vmax) decreased, indicating that SPC acts as mixed-type inhibitor for AChE. The analysis of SPC analogs clarified the importance of both the quaternary ammonium cation and the carbon chain length of SPC for the AChE inhibitory effect and showed that SPC was unique in AChE inhibition among the sphingolipids in this study. These findings indicate a novel function of SPC on AChE inhibition. Thus, the inhibition activity of SPC may be a factor in the increase of ACh in AD.</description><subject>acetylcholine</subject><subject>Acetylcholinesterase</subject><subject>Acetylcholinesterase - metabolism</subject><subject>acetylcholinesterase inhibitor</subject><subject>Ammonium</subject><subject>Atopic dermatitis</subject><subject>Cholinesterase Inhibitors - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Eczema</subject><subject>Humans</subject><subject>Neostigmine - pharmacology</subject><subject>Phosphorylcholine - analogs &amp; derivatives</subject><subject>Phosphorylcholine - pharmacology</subject><subject>Pruritus</subject><subject>quaternary ammonium cation</subject><subject>Rivastigmine - pharmacology</subject><subject>Skin diseases</subject><subject>sphingolipid</subject><subject>Sphingolipids</subject><subject>Sphingosine - analogs &amp; derivatives</subject><subject>Sphingosine - pharmacology</subject><subject>Sphingosylphosphorylcholine</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhq0KRJe2x15RJC5cUjz-iJPjqrSlUgUH4Gw5jtN45Y2D7VTaf493U4LEwTOS55l3vhC6BnwDhNWf26m9aQmUGDOoztAGKBMlJ8DfoA1uoC4r4PU5eh_jDmMsMKHv0HlmoKlYvUG7bfHNvxhX3M-jTtaPhe-LH9Ngx2cfD24afMwvHJwevLOjKTKRBlM8joNtbcqR4q7vjU7xmLjVJq1oTCaoaPJnsi82HS7R2165aK5e_QX6dX_38_Zr-fT94fF2-1TqijepbJTKk9RCK4551RJFu1ZhTjUTuutYQysqaqC14QCKV6pRXAEXHesoazloeoE-LbpT8L_n3Ibc26iNc2o0fo6S8AYIYCGajH78D935OYy5uxPFgOKaZ6pcKB18jMH0cgp2r8JBApbHI8h8BJmPIE9HyPyHV9W53Ztupf9uPQMPC5CjVivnx-O-_tXWUbTWOy8JXkQZZAdCgjgZQmmTK5HjAF8WpV1M6tmspVRIVjtzaowxmdOzXTtcw3pQQZqR_gGe8rGj</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Kitazawa, Kazuyuki</creator><creator>Nagasawa-Shimura, Nanako</creator><creator>Tanaka, Kazunori</creator><creator>Musashi, Mina</creator><creator>Kubota, Yoshiki</creator><creator>Nagasawa, Teruaki</creator><creator>Yamaguchi, Yoko</creator><general>The Pharmaceutical Society of Japan</general><general>Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20211101</creationdate><title>A Novel Function of Sphingosylphosphorylcholine on the Inhibitory Effects of Acetylcholinesterase Activity</title><author>Kitazawa, Kazuyuki ; Nagasawa-Shimura, Nanako ; Tanaka, Kazunori ; Musashi, Mina ; Kubota, Yoshiki ; Nagasawa, Teruaki ; Yamaguchi, Yoko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c659t-9aa41687ca5056b2a3dba053c47cdd4936378138e511a56a9a5a157d4d34b51c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>acetylcholine</topic><topic>Acetylcholinesterase</topic><topic>Acetylcholinesterase - metabolism</topic><topic>acetylcholinesterase inhibitor</topic><topic>Ammonium</topic><topic>Atopic dermatitis</topic><topic>Cholinesterase Inhibitors - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Eczema</topic><topic>Humans</topic><topic>Neostigmine - pharmacology</topic><topic>Phosphorylcholine - analogs &amp; derivatives</topic><topic>Phosphorylcholine - pharmacology</topic><topic>Pruritus</topic><topic>quaternary ammonium cation</topic><topic>Rivastigmine - pharmacology</topic><topic>Skin diseases</topic><topic>sphingolipid</topic><topic>Sphingolipids</topic><topic>Sphingosine - analogs &amp; derivatives</topic><topic>Sphingosine - pharmacology</topic><topic>Sphingosylphosphorylcholine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kitazawa, Kazuyuki</creatorcontrib><creatorcontrib>Nagasawa-Shimura, Nanako</creatorcontrib><creatorcontrib>Tanaka, Kazunori</creatorcontrib><creatorcontrib>Musashi, Mina</creatorcontrib><creatorcontrib>Kubota, Yoshiki</creatorcontrib><creatorcontrib>Nagasawa, Teruaki</creatorcontrib><creatorcontrib>Yamaguchi, Yoko</creatorcontrib><creatorcontrib>Inc</creatorcontrib><creatorcontrib>aNANOEGG(R Research Laboratories</creatorcontrib><creatorcontrib>bInstitute of Medical Science</creatorcontrib><creatorcontrib>St.Marianna University School of Medicine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kitazawa, Kazuyuki</au><au>Nagasawa-Shimura, Nanako</au><au>Tanaka, Kazunori</au><au>Musashi, Mina</au><au>Kubota, Yoshiki</au><au>Nagasawa, Teruaki</au><au>Yamaguchi, Yoko</au><aucorp>Inc</aucorp><aucorp>aNANOEGG(R Research Laboratories</aucorp><aucorp>bInstitute of Medical Science</aucorp><aucorp>St.Marianna University School of Medicine</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Function of Sphingosylphosphorylcholine on the Inhibitory Effects of Acetylcholinesterase Activity</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>44</volume><issue>11</issue><spage>1717</spage><epage>1723</epage><pages>1717-1723</pages><artnum>b21-00416</artnum><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>Acetylcholine (ACh), a quaternary ammonium cation, is known as one of the itch inducer in atopic dermatitis (AD), an inflammatory skin disease with intense itching. Previous research has reported accumulation of ACh in lesional site of AD patients. Generally, ACh is metabolized by cholinesterase (ChE). Therefore, one of the causes of ACh accumulation may be the suppression of ChE activity. Increased levels of the multifunctional bioactive sphingolipid sphingosylphosphorylcholine (SPC) have also been detected in AD. Since SPC possesses a quaternary ammonium cation, like ACh, it is possible that SPC affects the activity of ChE catalyzing ACh metabolization. We investigated whether SPC influences the activity of ChE by performing enzymatic analysis of ChE in the presence of SPC. We found that SPC strongly suppressed acetylcholinesterase (AChE) activity, but the suppression of butyrylcholinesterase by SPC was quite low. The Michaelis constant (Km) of AChE in the presence of SPC increased, and the maximum velocity (Vmax) decreased, indicating that SPC acts as mixed-type inhibitor for AChE. The analysis of SPC analogs clarified the importance of both the quaternary ammonium cation and the carbon chain length of SPC for the AChE inhibitory effect and showed that SPC was unique in AChE inhibition among the sphingolipids in this study. These findings indicate a novel function of SPC on AChE inhibition. Thus, the inhibition activity of SPC may be a factor in the increase of ACh in AD.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>34719648</pmid><doi>10.1248/bpb.b21-00416</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2021/11/01, Vol.44(11), pp.1717-1723
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_2591210779
source J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry
subjects acetylcholine
Acetylcholinesterase
Acetylcholinesterase - metabolism
acetylcholinesterase inhibitor
Ammonium
Atopic dermatitis
Cholinesterase Inhibitors - pharmacology
Dose-Response Relationship, Drug
Eczema
Humans
Neostigmine - pharmacology
Phosphorylcholine - analogs & derivatives
Phosphorylcholine - pharmacology
Pruritus
quaternary ammonium cation
Rivastigmine - pharmacology
Skin diseases
sphingolipid
Sphingolipids
Sphingosine - analogs & derivatives
Sphingosine - pharmacology
Sphingosylphosphorylcholine
title A Novel Function of Sphingosylphosphorylcholine on the Inhibitory Effects of Acetylcholinesterase Activity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A45%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Function%20of%20Sphingosylphosphorylcholine%20on%20the%20Inhibitory%20Effects%20of%20Acetylcholinesterase%20Activity&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Kitazawa,%20Kazuyuki&rft.aucorp=Inc&rft.date=2021-11-01&rft.volume=44&rft.issue=11&rft.spage=1717&rft.epage=1723&rft.pages=1717-1723&rft.artnum=b21-00416&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b21-00416&rft_dat=%3Cproquest_cross%3E2591210779%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2591413085&rft_id=info:pmid/34719648&rfr_iscdi=true